問卷

TPIDB > Search Result > Study Site

Study Site



National Taiwan University Hospital

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

篩選

List

3103Cases

2021-04-01 - 2022-09-30

Phase III

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
  • Condition/Disease

    Primary Immune Thrombocytopenia

  • Test Drug

    Rozanolixizumab

Participate Sites
8Sites

Not yet recruiting8Sites

2014-09-01 - 2016-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-11-01 - 2015-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-06-01 - 2015-02-20

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-06-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-07-01 - 2020-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2013-01-01 - 2015-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease
  • Condition/Disease

    Alzeheimer's Disease

  • Test Drug

    LMTM

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

2015-02-01 - 2017-12-31

Phase III

TRx-237-020: An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis (hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia
  • Condition/Disease

    Alzheimer’s Disease

  • Test Drug

    Leuco-methylthioninium bis (hydromethanesulfonate) (LMTM, TRx0237)

Participate Sites
4Sites

Terminated4Sites

2016-03-07 - 2017-12-31

Phase III

A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease
  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    RVT-101

Participate Sites
5Sites

Terminated4Sites